Method for vascular occlusive therapy in gastrointestinal system
A method for treating a blood vessel in a wall forming a gastrointestinal tract of a body of a mammal. An occlusion is formed in the vessel so as to terminate blood flow to the vessel distal of the occlusion. A method for treating a varix in a gastrointestinal wall, a method of treating an ulcer in a gastrointestinal wall, and a method for treating a hemorrhoid in a rectal wall are also provided.
1 . A method for use in a body of a mammal having an internal wall forming a gastrointestinal tract to treat a blood vessel in the wall comprising forming an occlusion in the vessel so as to terminate blood flow to the vessel distal of the occlusion.
2 . The method of claim 1 wherein the step of forming an occlusion in the vessel includes introducing solution of a biocompatible polymer and a biocompatible solvent to form a non-biodegradable solid in the vessel.
3 . The method of claim 2 wherein the solution of the biocompatible polymer and the biocompatible solvent has a composition comprising from about 2.5 to about 8.0 weight percent of a biocompatible polymer, from about 10 to about 40 weight percent of a water insoluble biocompatible contrast agent and from about 52 to about 87.5 weight percent of a biocompatible solvent.
4 . The method of claim 2 wherein the solution of the biocompatible polymer and the biocompatible solvent has a composition comprising from about 2.5 to about 8.0 weight percent of a biocompatible polymer, from about 10 to about 40 weight percent of a water soluble biocompatible contrast agent and from about 52 to about 87.5 weight percent of a biocompatible solvent.
5 . The method of claim 2 wherein the introducing step includes the steps of extending a needle into vessel and supplying the biocompatible polymer and the biocompatible solvent through the needle into the vessel.
6 . The method of claim 5 wherein the introducing step includes the step of introducing the needle through the mouth and into the gastrointestinal tract.
7 . The method of claim 6 wherein the vessel is an enlarged varix in the vicinity of the gastroesophageal sphincter.
8 . The method of claim 6 wherein the vessel is an ulcer in the gastrointestinal tract.
9 . The method of claim 5 wherein the introducing step includes the step of introducing the needle through the anus and into the anal canal of the gastrointestinal tract.
10 . The method of claim 9 wherein the vessel is a hemorrhoid in the anal canal.
11 . The method of claim 1 wherein the vessel is an enlarged varix in the vicinity of the gastroesophageal sphincter.
12 . The method of claim 1 wherein the vessel is an ulcer.
13 . The method of claim 1 further comprising the step of forming at least one implant in the wall in the vicinity of the gastrointestinal tract to create a tamponade.
14 . The method of claim 1 wherein the vessel is a hemorrhoid in the anal canal.
15 . The method of claim 1 wherein the mammal is a human.
16 . The method of claim 1 further comprising the step of ligating a portion of the vessel.
17 . The method of claim 1 further comprising the step of introducing a clotting agent into the vessel.
18 . The method of claim 1 further comprising the step of cauterizing the vessel.
19 . A method for treating a varix in a gastrointestinal wall of a body of a mammal having a blood vessel in the wall leading to the varix comprising forming an occlusion in the vessel so as to limit blood flow to the varix.
20 . The method of claim 19 wherein the step of forming an occlusion in the vessel includes introducing a solution of a biocompatible polymer and a biocompatible solvent to form a non-biodegradable solid in the vessel.
21 . The method of claim 20 wherein the solution of the biocompatible polymer and the biocompatible solvent has a composition comprising from about 2.5 to about 8.0 weight percent of a biocompatible polymer, from about 10 to about 40 weight percent of a water insoluble biocompatible contrast agent and from about 52 to about 87.5 weight percent of a biocompatible solvent.
22 . The method of claim 20 wherein the solution of the biocompatible polymer and the biocompatible solvent has a composition comprising from about 2.5 to about 8.0 weight percent of a biocompatible polymer, from about 10 to about 40 weight percent of a water soluble biocompatible contrast agent and from about 52 to about 87.5 weight percent of a biocompatible solvent.
23 . The method of claim 20 wherein the introducing step includes the steps of extending a needle into vessel and supplying the biocompatible polymer and the biocompatible solvent through the needle into the vessel.
24 . A method for treating an ulcer in a gastrointestinal wall of a body of a mammal having a blood vessel in the wall leading to the ulcer comprising forming an occlusion in the vessel so as to limit blood flow to the ulcer
25 . The method of claim 24 wherein the step of forming an occlusion in the vessel includes introducing a solution of a biocompatible polymer and a biocompatible solvent to form a non-biodegradable solid in the vessel.
26 . The method of claim 25 wherein the solution of the biocompatible polymer and the biocompatible solvent has a composition comprising from about 2.5 to about 8.0 weight percent of a biocompatible polymer, from about 10 to about 40 weight percent of a water insoluble biocompatible contrast agent and from about 52 to about 87.5 weight percent of a biocompatible solvent.
27 . The method of claim 25 wherein the solution of the biocompatible polymer and the biocompatible solvent has a composition comprising from about 2.5 to about 8.0 weight percent of a biocompatible polymer, from about 10 to about 40 weight percent of a water soluble biocompatible contrast agent and from about 52 to about 87.5 weight percent of a biocompatible solvent.
28 . The method of claim 25 wherein the introducing step includes the steps of extending a needle into vessel and supplying the biocompatible polymer and the biocompatible solvent through the needle into the vessel.
29 . A method for treating a hemorrhoid in a rectal wall of a body of a mammal having a blood vessel in the wall leading to the hemorrhoid comprising forming an occlusion in the vessel so as to limit blood flow to the hemorrhoid.
30 . The method of claim 29 wherein the step of forming an occlusion in the vessel includes introducing a solution of a biocompatible polymer and a biocompatible solvent to form a non-biodegradable solid in the vessel.
31 . The method of claim 30 wherein the solution of the biocompatible polymer and the biocompatible solvent has a composition comprising from about 2.5 to about 8.0 weight percent of a biocompatible polymer, from about 10 to about 40 weight percent of a water insoluble biocompatible contrast agent and from about 52 to about 87.5 weight percent of a biocompatible solvent.
32 . The method of claim 30 wherein the solution of the biocompatible polymer and the biocompatible solvent has a composition comprising from about 2.5 to about 8.0 weight percent of a biocompatible polymer, from about 10 to about 40 weight percent of a water soluble biocompatible contrast agent and from about 52 to about 87.5 weight percent of a biocompatible solvent.
33 . The method of claim 30 wherein the introducing step includes the steps of extending a needle into vessel and supplying the biocompatible polymer and the biocompatible solvent through the needle into the vessel.
34 . A method for use in a body of a mammal having an internal wall forming a gastrointestinal tract to treat a blood vessel in the wall comprising introducing a material through the gastrointestinal tract into the vessel to create an occlusion in the vessel and thus limit blood flow to the vessel distal of the occlusion.
35 . The method of claim 34 wherein the solution of the biocompatible polymer and the biocompatible solvent has a composition comprising from about 2.5 to about 8.0 weight percent of a biocompatible polymer, from about 10 to about 40 weight percent of a water insoluble biocompatible contrast agent and from about 52 to about 87.5 weight percent of a biocompatible solvent.
36 . The method of claim 35 wherein the solution of the biocompatible polymer and the biocompatible solvent has a composition comprising from about 2.5 to about 8.0 weight percent of a biocompatible polymer, from about 10 to about 40 weight percent of a water soluble biocompatible contrast agent and from about 52 to about 87.5 weight percent of a biocompatible solvent.
37 . The method of claim 35 wherein the introducing step includes the steps of extending a needle into vessel and supplying the biocompatible polymer and the biocompatible solvent through the needle into the vessel.